Skip to main content
. 2019 Mar 21;5(6):833–840. doi: 10.1001/jamaoncol.2019.0001

Figure 2. Progression-Free Survival and Overall Survival of the Study Cohort.

Figure 2.

Following a 2-sided log-rank test after a median follow-up period of 7 years, among patients in the doxorubicin plus cisplatin (AP) treatment group, docetaxel plus cisplatin (DP) treatment group, and paclitaxel plus carboplatin (TC) treatment group, there was no statistical difference of progression-free survival (A) (AP, 72 of 263 patients; DP, 55 of 263 patients; TC, 75 of 262 patients; P = .12) nor overall survival (B) (AP, 46 of 263 patients; DP, 40 of 263 patients; TC, 47 of 262 patients; P = .67).